MGTA-117 Antibody 

MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy^[1][2][3].

Human

c-Kit/CD117

MGTA-117 (0.1-1.0 mg/kg) 快速选择性结合并清除 CD117+细胞 (人类造血干细胞和 AML 肿瘤细胞)，其 IC₅₀ 均 <10 pM^[1]。
MGTA-117 可有效清除 AML 小鼠模型中 95% 以上人类造血祖细胞 (HSPCs)^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MGTA-117 (0.1 mg/kg, i.v., once for 21 days) has a short half-life with a t_1/2 of 91 h and selectively depletes ≥95% HSPCs in humanized NSG (hNSG) mice^[1,2].
MGTA-117(3 & 10 mg/kg, once or 3 mg/kg, QODx2) significantly increases survival of a 2.4-2.7-fold in Kasumi-1 xenograft hNSG mice model^[2].
MGTA-117 (3 & 10 mg/kg, once) significantly decreases peripheral tumor burden, delays tumor growth, and increases survival in AML PDX 1 (2-3.3 fold) and AML PDX 2 (1.3-1.8 fold) xenograft hNSG mice models^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3815  [NCBI]

P10721

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Artz A S, et al. TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB) [J]. 2022.

  [2]. Lanieri L, et al. A single dose of a novel anti-human CD117-amanitin antibody drug conjugate (ADC) engineered for a short half-life provides dual conditioning and anti-leukemic activity and extends survival compared to standard of care in multiple preclinical models of acute myeloid leukemia (AML)[J]. Blood, 2020, 136: 47-48.

  [3]. Kitawi R, et al. Advances in HIV Gene Therapy. Int J Mol Sci. 2024 Feb 28; 25(5):2771.  [Content Brief]